ClinicalTrials.gg
TerminatedNCT02959437Updated Oct 21, 2025Results posted

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

A Phase 1/2 interventional study of Azacitidine and Pembrolizumab in Solid Tumors, Advanced Malignancies and Metastatic Cancer, sponsored by Incyte Corporation. Terminated at 12 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-21.

Sponsored by Incyte Corporation · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Study terminated by Sponsor

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Neoplasm Metastasis by Incyte Corporation — none open to participants now, none under way, none of them phase 3. Neoplasm Metastasis · Incyte Corporation.

Enrollment
10th of 19
70 · median 70
Started
2017
with 2 others
Phase 1/2
7 of 19
none open now
Registered
8th of 19
by date

Among the 19 studies in Neoplasm Metastasis by Incyte Corporation, this one is the 10th largest by enrollment, is one of 3 that started in 2017, is one of 7 in phase 1/2, and was the 8th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

None of the 19 studies in Neoplasm Metastasis by Incyte Corporation is open now. The open studies under Neoplasm Metastasis, anywhere →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Neoplasm Metastasis by Incyte Corporation as a file.
02

Study summary

This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination. Treatment Group A will evaluate the DNA methyltransferase inhibitor azacitidine in combination with the programmed death receptor-1 (PD-1) inhibitor pembrolizumab and the indoleamine 2,3-dioxygenase (IDO-1) inhibitor epacadostat; Treatment Group B will evaluate the bromodomain and extra-terminal (BET) inhibitor INCB057643 with pembrolizumab and epacadostat; and Treatment Group C will evaluate the lysine-specific demethylase 1A (LSD1) inhibitor INCB059872 with pembrolizumab and epacadostat. The study will be divided into 2 parts (Part 1 and 2). Part 1 is a dose-escalation assessment to evaluate the safety and tolerability of the combination therapies. Once the recommended doses have been determined, subjects with previously treated NSCLC, microsatellite-stable colorectal cancer (CRC), head and neck squamous cell carcinoma, urothelial carcinoma, and melanoma will be enrolled into expansion cohorts in Part 2.

03

Conditions studied

  • Solid Tumors
  • Advanced Malignancies
  • Metastatic Cancer

Browse trials for

Keywords

  • Solid tumors
  • NSCLC
  • CRC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness to provide written for the study.
  • Willingness to undergo a pretreatment and on-treatment tumor to obtain tumor tissue.
  • (ECOG) performance status of 0 or 1.
  • Part 1: Subjects with or cytologically confirmed advanced or solid tumors that have failed prior standard therapy (disease progression; subject refusal or intolerance is also allowable).
  • Part 2:

    *Note: Subjects must have failed available therapies that are known to confer clinical benefit as indicated below, unless they are ineligible, intolerant, or refused standard treatment.

  • Subjects with histologically or cytologically confirmed NSCLC:

    • Metastatic (Stage IV) or recurrent NSCLC (according to American Joint Committee on Cancer 7th edition guidelines) who have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment.
    • Prior systemic regimens must include previously approved therapies, including a platinum-containing chemotherapy regimen; a tyrosine kinase inhibitor for tumors with driver mutations; and where approved.
    • Must have disease progression on a prior PD-1-pathway targeted agent.
  • Subjects with recurrent (unresectable) or metastatic CRC:

    • Have histologically confirmed microsatellite stable (MSS) CRC.
    • Stage IV MSS CRC (according to American Joint Committee on Cancer 7th edition guidelines) who have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment.
    • Prior systemic regimens must include previously approved therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy (if no ); and if negative for KRAS, NRAS, and BRAF mutations and no contraindication, an anti-epidermal growth factor receptor (EGFR) therapy; and progressed after the last administration of approved therapy.
  • Subjects with HNSCC:

    • Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx.
    • Carcinomas of the nasopharynx, salivary gland, or nonsquamous cell histology are excluded.
    • Must have received prior treatment with a platinum-based therapy
    • Must have had documented disease progression while on a prior PD-1 pathway-targeted agent.
  • Subjects with melanoma:

    • Histologically or cytologically confirmed melanoma.
    • Unresectable Stage III or Stage IV melanoma, as per American Joint Committee on Cancer staging system not amenable to local therapy.
  • Subjects with urothelial carcinoma:

    • Histologically or cytologically confirmed urothelial carcinoma of the renal pelvis, ureter, urinary bladder, or urethra that is transitional cell or mixed transitional/nontransitional (predominantly transitional) cell type.
    • Stage IV locally advanced or metastatic urothelial carcinoma (according to American Joint Committee on Cancer 7th edition guidelines) with documented disease progression while on a PD-1 pathway targeted therapy.

Exclusion criteria

Exclusion Criteria:

  • Laboratory parameters not within the protocol-defined range.
  • Receipt of anticancer medications or drugs within a defined interval before the first administration of study drug.
  • Has not recovered from toxic effects of prior therapy to ≤ Grade 1.
  • Active or inactive disease or syndrome.
  • Active infection requiring systemic therapy.
  • Known active central nervous system (CNS) and/or carcinomatous meningitis.
  • History or presence of an abnormal that, in the investigator's opinion, is .
  • Has received a within 30 days of planned start of study therapy.
  • Prior receipt of an IDO inhibitor.
  • Subjects with uncontrolled type I or type II diabetes mellitus (defined as HgbA1c > 8).
  • Prior receipt of a BET inhibitor (Treatment Group B only).
  • Subjects with a history of bleeding related to cancer under study requiring a medical intervention (eg, embolization procedure, RBC transfusion, or hospitalization) within 30 days of study enrollment (Treatment Groups B and C only).
  • Clinically significant bleeding within 14 days of Cycle 1 Day 1 (Treatment Groups B and C only).
  • Prior receipt of an LSD1 inhibitor including INCB059872 (Treatment Group C only).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Treatment Group A: Azacitidine + Pembrolizumab + Epacadostat

    Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.

    Drug: Azacitidine · Drug: Pembrolizumab · Drug: Epacadostat

  • Experimental
    Treatment Group B: INCB057643 + Pembrolizumab + Epacadostat

    Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.

    Drug: INCB057643 · Drug: Pembrolizumab · Drug: Epacadostat

  • Experimental
    Treatment Group C: INCB059872 + Pembrolizumab + Epacadostat

    Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.

    Drug: Pembrolizumab · Drug: Epacadostat · Drug: INCB059872

Interventions

  • Five doses of azacitidine will be administered by subcutaneous injection or intravenously (IV) over Days 1 to 7 in Cycles 1 through 6.

  • Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks on Day 1 of each 21-day cycle.

  • Epacadostat tablets will be administered orally twice daily.

  • INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.

  • Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks of each 21-day cycle starting on Cycle 2 Day 1.

  • Epacadostat tablets will be administered orally twice daily starting at Cycle 2 Day 1.

  • INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.

06

What researchers measure

Primary outcomes

  1. Part 1 and 2 : Number of Participants With Treatment Emergent Adverse Events

    A treatment-emergent AE was defined as an event occurring after exposure to at least 1 dose of study drug. A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).

    Time frame: Baseline through 42-49 days after end of treatment, estimated up to 27 months (24 months with 100 day FU period).

  2. Part 1 and 2: Objective Response Rate Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. A participant was considered as an objective responder if the participant had a best overall response of CR or PR.

    Time frame: Every 9 weeks for the duration of study participation; estimated minimum of 6 months.

Secondary outcomes

  1. Parts 1 and 2: Percentage of Responders Determined by Immunohistochemistry

    Responder is defined as an increase in the number of tumor-infiltrating lymphocytes or the ratio of CD8+ lymphocytes to T regulatory cells infiltrating tumor post-treatment versus pretreatment with pembrolizumab and epacadostat in combination with azacitidine.

    Time frame: Baseline to Week 5/6 or week 8/9

  2. Parts 1 and 2: Progression-free Survival Based on RECIST v1.1.

    Defined as the time from date of first dose of study drug until the earliest date of disease progression per RECIST v1.1, or death due to any cause, if occurring sooner than progression.

    Time frame: Every 9 weeks from date of randomization until the date of first documented progression or date of death from any cause whichever came first, assessed up to 24 months

  3. Parts 1 and 2: Duration of Response Based on RECIST v1.1

    Defined as the time from earliest date of disease response until the earliest date of disease progression per RECIST v1.1, or death due to any cause, if occurring sooner than progression.

    Time frame: Every 9 weeks from date of randomization until the date of first documented progression or date of death from any cause whichever came first, assessed up to 24 months

07

Results

Posted Mar 5, 2020

Participant flow

The study was conducted at 8 study sites in United States, 2 sites in UK and 1 site in Spain.

Participant flow — Overall Study
MilestoneTreatment Group A :100mg of INCB24360Treatment Group A :300mg of INCB24360Treatment Group B :INCB057643+Pembrolizumab+EpacadostatTreatment Group C :INCB059872+Pembrolizumab+Epacadostat
Started62800
Completed0000
Not completed62800
Withdrew: Death33300
Withdrew: Lost to follow-up3100
Withdrew: Withdrawal by subject11300
Withdrew: Progressive disease9100
Withdrew: Study terminated by sponsor4000
Withdrew: Other unspecified2000

Outcome measures

PrimaryPart 1 and 2 : Number of Participants With Treatment Emergent Adverse Events

A treatment-emergent AE was defined as an event occurring after exposure to at least 1 dose of study drug. A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).

Time frame:
Baseline through 42-49 days after end of treatment, estimated up to 27 months (24 months with 100 day FU period).
Reported as:
Count of participants · Participants
Part 1 and 2 : Number of Participants With Treatment Emergent Adverse Events
ParticipantsTreatment Group A :100mg of INCB24360Treatment Group A :300mg of INCB24360Treatment Group B :INCB057643+Pembrolizumab+EpacadostatTreatment Group C :INCB059872+Pembrolizumab+Epacadostat
Part 1 and 2 : Number of Participants With Treatment Emergent Adverse Events628——
PrimaryPart 1 and 2: Objective Response Rate Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. A participant was considered as an objective responder if the participant had a best overall response of CR or PR.

Time frame:
Every 9 weeks for the duration of study participation; estimated minimum of 6 months.
Reported as:
Count of participants · Participants
Part 1 and 2: Objective Response Rate Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
ParticipantsTreatment Group A :100mg of INCB24360Treatment Group A :300mg of INCB24360Treatment Group B :INCB057643+Pembrolizumab+EpacadostatTreatment Group C :INCB059872+Pembrolizumab+Epacadostat
Part 1 and 2: Objective Response Rate Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)3100
SecondaryParts 1 and 2: Percentage of Responders Determined by Immunohistochemistry

Responder is defined as an increase in the number of tumor-infiltrating lymphocytes or the ratio of CD8+ lymphocytes to T regulatory cells infiltrating tumor post-treatment versus pretreatment with pembrolizumab and epacadostat in combination with azacitidine.

Time frame:
Baseline to Week 5/6 or week 8/9
Reported as:
Count of participants · Participants
Parts 1 and 2: Percentage of Responders Determined by Immunohistochemistry
ParticipantsTreatment Group A :100 or 300mg of INCB24360Treatment Group B :INCB057643+Pembrolizumab+EpacadostatTreatment Group C :INCB059872+Pembrolizumab+Epacadostat
Intratumoral CD8+ T cells14——
CD8+:FoxP3+ ratios10——
SecondaryParts 1 and 2: Progression-free Survival Based on RECIST v1.1.

Defined as the time from date of first dose of study drug until the earliest date of disease progression per RECIST v1.1, or death due to any cause, if occurring sooner than progression.

Time frame:
Every 9 weeks from date of randomization until the date of first documented progression or date of death from any cause whichever came first, assessed up to 24 months
Reported as:
Median · Months
Parts 1 and 2: Progression-free Survival Based on RECIST v1.1.
MonthsTreatment Group A :100mg of INCB24360Treatment Group A :300mg of INCB24360Treatment Group B :INCB057643+Pembrolizumab+EpacadostatTreatment Group C :INCB059872+Pembrolizumab+Epacadostat
Parts 1 and 2: Progression-free Survival Based on RECIST v1.1.2.07 (1.97 to 2.17)2.64 (1.31 to 6.11)——
SecondaryParts 1 and 2: Duration of Response Based on RECIST v1.1

Defined as the time from earliest date of disease response until the earliest date of disease progression per RECIST v1.1, or death due to any cause, if occurring sooner than progression.

Time frame:
Every 9 weeks from date of randomization until the date of first documented progression or date of death from any cause whichever came first, assessed up to 24 months
Reported as:
Median · Months
Parts 1 and 2: Duration of Response Based on RECIST v1.1
MonthsTreatment Group A :100mg of INCB24360Treatment Group A :300mg of INCB24360Treatment Group B :INCB057643+Pembrolizumab+EpacadostatTreatment Group C :INCB059872+Pembrolizumab+Epacadostat
Parts 1 and 2: Duration of Response Based on RECIST v1.12.63 (2.20 to 21.85)1.22 (NA to NA)——

Adverse events

Collected over Baseline through 42-49 days after end of treatment, estimated up to 27 months (24 months with 100 day FU period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Group A :100mg of INCB2436041/62 (66.1%)28/62 (45.2%)59/62 (95.2%)
Treatment Group A :300mg of INCB243604/8 (50%)3/8 (37.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventTreatment Group A :100mg of INCB24360Treatment Group A :300mg of INCB24360
Disease ProgressionGeneral disorders8/620/8
LeukocytosisBlood and lymphatic system disorders0/621/8
Sinua tachycardiaCardiac disorders0/621/8
Abdominal PainGastrointestinal disorders2/621/8
NauseaGastrointestinal disorders4/621/8
VomitingGastrointestinal disorders2/621/8
AstheniaGeneral disorders0/621/8
Non-cardiac Chest PainGeneral disorders0/621/8
InfectionInfections and infestations0/621/8
Head InjuryInjury, poisoning and procedural complications0/621/8
Most frequent other events
Showing 10 of 66
Most frequent other events
EventTreatment Group A :100mg of INCB24360Treatment Group A :300mg of INCB24360
FatigueGeneral disorders28/626/8
Decreased appetiteMetabolism and nutrition disorders12/625/8
NauseaGastrointestinal disorders34/623/8
HeadacheNervous system disorders4/624/8
ConstipationGastrointestinal disorders16/623/8
Aspartate aminotransferase increasedInvestigations5/623/8
DiarrhoeaGastrointestinal disorders12/623/8
VomitingGastrointestinal disorders21/622/8
AnaemiaBlood and lymphatic system disorders11/622/8
Abdominal DistensionGastrointestinal disorders2/622/8

Baseline characteristics

No patients enrolled in Treatment Group B and C.

Age, Continuous
Age, Continuous(years)Treatment Group A :100mg of INCB24360Treatment Group A :300mg of INCB24360Treatment Group B :INCB057643+Pembrolizumab+EpacadostatTreatment Group C :INCB059872+Pembrolizumab+EpacadostatTotal
Mean57.0 ± 11.9253.0 ± 11.31——56.5 ± 11.84
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Group A :100mg of INCB24360Treatment Group A :300mg of INCB24360Treatment Group B :INCB057643+Pembrolizumab+EpacadostatTreatment Group C :INCB059872+Pembrolizumab+EpacadostatTotal
Female194——23
Male434——47
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment Group A :100mg of INCB24360Treatment Group A :300mg of INCB24360Treatment Group B :INCB057643+Pembrolizumab+EpacadostatTreatment Group C :INCB059872+Pembrolizumab+EpacadostatTotal
White/Caucasian565——61
Black/African-American30——3
Asian20——2
American-Indian/Alaska Native00——0
Native Hawaiian/Pacific Islander00——0
Other13——4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment Group A :100mg of INCB24360Treatment Group A :300mg of INCB24360Treatment Group B :INCB057643+Pembrolizumab+EpacadostatTreatment Group C :INCB059872+Pembrolizumab+EpacadostatTotal
Hispanic or Latino — Hispanic or Latino42006
Hispanic or Latino — Not Hispanic or Latino5460060
Hispanic or Latino — Unknown40004
08

Study locations

12 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of California San Diego
    La Jolla, California 92093, United States
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • University of Pennsylvania Health System
    Philadelphia, Pennsylvania 19014, United States
  • Sarah Cannon
    Nashville, Tennessee 37203, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Washington
    Seattle, Washington 98109, United States
  • Vall D Hebron Univ
    Barcelona, 08035, Spain
  • Univ De Navarra
    Pamplona, 31008, Spain
  • University College London Hospitals (Uclh)
    London, W1t7ha, United Kingdom
  • Churchill Hospital
    Oxford, Ox37le, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Feb 2019, 23 months.

Results were first posted in Mar 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2016
First posted
Nov 9, 2016
StartActual
Feb 27, 2017
Primary completionActual
Feb 15, 2019
CompletionActual
Mar 2, 2020
Results first posted
Mar 5, 2020
Last update
Oct 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02959437
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 9, 2016
Start date
Feb 27, 2017
Primary completion
Feb 15, 2019
Completion
Mar 2, 2020
Results posted
Mar 5, 2020
Last update
Oct 21, 2025

Study contacts

Kevin O'Hayer, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azacitidine · INCB057643 · INCB059872

Start the discussion